All In Biotech

Drug Trial Radar · NCT02160548

Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP Poisoning

Effect of Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen During Resuscitation of OP Pesticide Poisoned Patients

Last checked: Nov 19, 2026Latest source record: Dec 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

75

Actual

Start

Apr 2015

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Sylhet M.A.G.Osmani Medical CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Edinburgh
First posted
Jun 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

We hypothesize that salbutamol will speed removal of alveolar fluid compared to atropine alone in OP poisoned patients. We propose to compare the effect of two stat doses of nebulized salbutamol (2.5 mg; 5.0 mg), with nebulized saline placebo, in symptomatic patients receiving standard resuscitation with atropine, oxygen, and fluids after poisoning with OP pesticides. 25 patients will be randomised to each arm (total 75 patients). Primary outcome will be oxygen saturation's over the following 60 min during resuscitation. Secondary outcomes will include atropine dose administered, speed to stabilization, aspiration or pneumonia, intubation, tachydysrhythmias, and mortality. A positive outcome will result in design of a large definitive phase III study.

Conditions

  • Organophosphate Poisoning

Interventions

  • Standard careDrug

    Standard management for OP poisoning

  • Standard care+ 2.5 mg SalbutamolDrug

    Ventolin respiratory solution 2.5 mg

  • Standard care+ 5 mg SalbutamolDrug

    Ventolin respiratory solution 5 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement of oxygen saturationTime frame: 60 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sylhet M.A.G.Osmani Medical College Hospital

    Sylhet, Sylhet Division, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.